Skip to main content
Premium Trial:

Request an Annual Quote

Appeal Lost

Carlo Croce, an Ohio State University cancer researcher, has lost his latest court appeal, Retraction Watch reports.

Croce both sued the New York Times following its publication of a piece that reported on allegations of research misconduct that had been brought against him and Purdue University's David Sanders for comments he made in the Times article and in a Lafayette Journal Courier article. In 2018, a judge largely dismissed the libel suit Croce brought against the Times.

Last May, as Retraction Watch then reported, a US federal judge ruled against Croce in his defamation suit against Sanders. It now adds that Croce has lost the appeal he made in that case, as three Sixth Circuit of Appeals judges upheld the earlier ruling, with the judges noting that journals have raised concerns about some papers from Croce. For instance, in 2017, the Proceedings of the National Academy of Sciences issued two expressions of concern regarding papers published by Croce, and Retraction Watch says Croce has had 10 papers retracted.

Croce is also suing Ohio State to be reinstated as department chair, saying he was improperly forced out.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.